Amundi Raises Stake in Collegium Pharmaceutical, Inc. $COLL

Amundi lifted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 302.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,592 shares of the specialty pharmaceutical company’s stock after buying an additional 47,024 shares during the quarter. Amundi owned approximately 0.19% of Collegium Pharmaceutical worth $1,816,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Wealthquest Corp purchased a new position in shares of Collegium Pharmaceutical in the first quarter worth $62,000. Virtus Fund Advisers LLC lifted its holdings in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Collegium Pharmaceutical in the first quarter worth $244,000. State of Wyoming lifted its holdings in shares of Collegium Pharmaceutical by 75.0% in the fourth quarter. State of Wyoming now owns 9,818 shares of the specialty pharmaceutical company’s stock worth $281,000 after buying an additional 4,208 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 28.8% in the fourth quarter. ProShare Advisors LLC now owns 11,196 shares of the specialty pharmaceutical company’s stock worth $321,000 after buying an additional 2,506 shares in the last quarter.

Collegium Pharmaceutical Trading Down 4.5%

COLL stock opened at $37.32 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 35.88 and a beta of 0.63. The firm’s fifty day simple moving average is $35.00 and its two-hundred day simple moving average is $30.92.

Collegium Pharmaceutical declared that its board has authorized a share buyback plan on Monday, July 7th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the transaction, the executive vice president owned 70,264 shares in the company, valued at $2,699,542.88. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Scott Dreyer sold 16,389 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at $3,959,052.73. This trade represents a 13.66% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,792 shares of company stock worth $2,084,207. 2.51% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

COLL has been the topic of several research analyst reports. HC Wainwright raised shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price on the stock in a report on Monday, August 11th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $42.33.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.